Sionna Therapeutics (NASDAQ:SION) Shares Down 10.1% – Time to Sell?

Shares of Sionna Therapeutics, Inc. (NASDAQ:SION) were down 10.1% on Monday . The company traded as low as $35.29 and last traded at $35.29. Approximately 28,699 shares were traded during mid-day trading, a decline of 91% from the average daily volume of 314,592 shares. The stock had previously closed at $39.25.

Wall Street Analyst Weigh In

A number of research analysts have issued reports on SION shares. Lifesci Capital began coverage on shares of Sionna Therapeutics in a research note on Tuesday, December 23rd. They set an “outperform” rating and a $60.00 target price for the company. Raymond James Financial reiterated a “strong-buy” rating and set a $53.00 price objective on shares of Sionna Therapeutics in a research report on Monday, January 5th. BTIG Research increased their price objective on Sionna Therapeutics from $50.00 to $58.00 and gave the stock a “buy” rating in a report on Wednesday, January 7th. Royal Bank Of Canada reaffirmed an “underperform” rating and set a $24.00 target price on shares of Sionna Therapeutics in a research note on Monday, December 1st. Finally, Weiss Ratings reissued a “sell (e+)” rating on shares of Sionna Therapeutics in a research note on Monday, December 29th. One analyst has rated the stock with a Strong Buy rating, six have given a Buy rating and two have issued a Sell rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $45.43.

Sionna Therapeutics Stock Performance

The company has a market cap of $1.62 billion and a P/E ratio of -7.46. The stock has a 50 day moving average price of $40.43 and a 200 day moving average price of $30.13.

Sionna Therapeutics (NASDAQ:SION) last issued its quarterly earnings results on Wednesday, November 5th. The company reported ($0.46) EPS for the quarter, topping the consensus estimate of ($0.52) by $0.06.

Insider Buying and Selling

In other Sionna Therapeutics news, Director Orbimed Advisors Llc sold 33,356 shares of Sionna Therapeutics stock in a transaction that occurred on Wednesday, December 24th. The shares were sold at an average price of $44.55, for a total value of $1,486,009.80. Following the transaction, the director owned 3,561,655 shares in the company, valued at approximately $158,671,730.25. The trade was a 0.93% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, Director Peter A. Thompson sold 33,356 shares of the company’s stock in a transaction on Wednesday, December 24th. The shares were sold at an average price of $44.55, for a total value of $1,486,009.80. Following the completion of the transaction, the director directly owned 3,561,655 shares in the company, valued at $158,671,730.25. This represents a 0.93% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 1,443,594 shares of company stock worth $54,494,015 over the last quarter. Insiders own 3.90% of the company’s stock.

Hedge Funds Weigh In On Sionna Therapeutics

A number of hedge funds have recently modified their holdings of the stock. Braidwell LP purchased a new stake in shares of Sionna Therapeutics during the second quarter valued at $18,770,000. Vanguard Group Inc. raised its holdings in Sionna Therapeutics by 81.4% during the 3rd quarter. Vanguard Group Inc. now owns 1,143,154 shares of the company’s stock worth $33,620,000 after buying an additional 512,803 shares during the period. Viking Global Investors LP lifted its stake in Sionna Therapeutics by 8.2% during the second quarter. Viking Global Investors LP now owns 3,195,181 shares of the company’s stock valued at $55,436,000 after buying an additional 242,427 shares in the last quarter. Aberdeen Group plc boosted its holdings in shares of Sionna Therapeutics by 27.4% in the second quarter. Aberdeen Group plc now owns 950,547 shares of the company’s stock worth $16,492,000 after buying an additional 204,583 shares during the period. Finally, Millennium Management LLC boosted its holdings in shares of Sionna Therapeutics by 1,425.5% in the third quarter. Millennium Management LLC now owns 214,085 shares of the company’s stock worth $6,296,000 after buying an additional 200,051 shares during the period.

Sionna Therapeutics Company Profile

Sionna Therapeutics is a clinical-stage biotechnology company dedicated to developing next-generation RNA therapeutics for oncology and immunology indications. Leveraging proprietary lipid nanoparticle and coacervate delivery technologies, the company aims to overcome key challenges associated with stability, targeting and immune activation that have historically limited the clinical performance of mRNA-based medicines. Its strategic focus spans both solid tumors and hematological malignancies, as well as selected autoimmune disorders, reflecting a broad ambition to harness the power of messenger RNA in diverse therapeutic areas.

At the heart of Sionna’s approach is a platform that combines optimized ionizable lipids with bespoke surface chemistries to enhance payload delivery, intracellular release and endosomal escape.